A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)

Clinical trial NCT05924880 · COMPLETED

Trial details

NCT number: NCT05924880
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Biliary Tract Cancers

Start date: 2023-07-21
Primary completion: 2025-02-07
Enrollment: 116

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.